Compare Charles River Laboratories Intl. Inc (CRL) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Mattel Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.51 (market cap $11.14B), while Mattel Inc trades at $13.8 (market cap $3.97B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.8× Mattel Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.
| CRL | MAT | |
|---|---|---|
Market Cap | $11.14B | $3.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $22.16 |
52-Week Low | $145.57 | $13.05 |
Enterprise Value | $14.00B | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Mattel (MAT) trades at $13.84, up 3.83% today, with a bullish technical signal and strong valuation metrics including a P/E of 8.86 and P/S of 0.81. Recent earnings showed a Q1 2026 beat but Q3-Q4 2025 misses, while revenue stability around $5.4B supports a 9.27% net margin. News highlights include Comic-Con exclusives and a Barbie-Dunkin' collaboration, though cash flow turned negative in 2025.
The stock presents value with low multiples and 50% analyst buy ratings, targeting $14.60 consensus. Risks include volatile earnings, debt load, and activist pressure for a sale. Upside depends on brand execution offsetting consumer spending sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
